Shanghai Zhiyu Biotechnology
AI-powered synthetic biology for sustainable bio-based materials
About Shanghai Zhiyu Biotechnology
Shanghai Zhiyu Biotechnology Co., Ltd., also known as Zelixir, is a company operating at the intersection of artificial intelligence and synthetic biology. Founded in 2021 by a team with expertise in molecular structure prediction, design algorithms, and synthetic biology, the firm aims to innovate the entire synthetic biology process using AI and biocomputing. The company's CEO is Dr. Sheng Wang.
Zelixir's core business revolves around the research, development, and production of bio-based raw materials for a variety of industries, including food, cosmetics, healthcare, and new materials. The company leverages its proprietary AI platforms—Yu Cloud ZCloud, Zhihui ZBot, and Zhishan ZPod—to redesign the synthetic biology workflow, from reaction pathway design and enzyme engineering to scaled-up production. This AI-driven approach is designed to significantly reduce R&D costs and accelerate the commercialization timeline for new products.
The company serves clients in sectors such as medical health, agriculture, food, consumer goods, and chemicals by offering high-quality bio-based materials and integrated research, production, and sales solutions. A key achievement is the development and impending large-scale production of Sustainable Natural Vanillin ex-Ferulic Acid. This product, created using AI-optimized enzymes, offers a sustainable and stable alternative to both natural and chemically synthesized vanillin and has received FEMA GRAS certification under the FDA. In late 2024, Zelixir announced the operational launch of a new green manufacturing plant in Changzhou, Jiangsu Province, to scale the production of its bio-based materials.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 13.0/100
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2023 | $14M | $55M | Shanghai Hongjia Private Equity Fund Management · Qiantang Industry Development Group · HM Capital · Ningbo Hongfeng Investment Management | ↗ |
| SEED✓Equity / VC | May 2022 | $6.9M | $28M | Hillhouse Capital | — |
Growth signals
Latest recorded traffic for Shanghai Zhiyu Biotechnology is 460 monthly website visits, down 44.6% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai Zhiyu Biotechnology in its local ecosystem
The Shanghai Zhiyu Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
- LCLaurel Venture Capital
CDH Investments
Hillhouse Capital
Series A4 investors entered at this stage
- SMShanghai Hongjia Private Equity Fund Management
- QGQiantang Industry Development Group
HM Capital- NMNingbo Hongfeng Investment Management
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Zhiyu Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Zhiyu Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.